The combination of HER2-targeted therapies, particularly trastuzumab-pertuzumab, with standard chemotherapy has revolutionized the treatment of HER2-positive advanced breast cancer (ABC), significantly improving patient outcomes, and representing a widely adopted standard of care regardless of estrogen receptor (ER) status [1–3]. This evidence concerns the gene ESR1 and aneurysmal bone cyst.